Загрузка...
Phase I/II study of S-1 combined with irinotecan for metastatic advanced gastric cancer
A dose-escalation study of irinotecan (CPT-11) combined with S-1, an oral dihydropyrimidine dehydrogenase inhibitory fluoropyrimidine, was performed to determine the maximum-tolerated dose (MTD), recommended dose (RD), dose-limiting toxicities (DLTs), and objective response rate (RR) in advanced gas...
Сохранить в:
| Главные авторы: | , , , , , , , |
|---|---|
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Nature Publishing Group
2006
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2361252/ https://ncbi.nlm.nih.gov/pubmed/16570038 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/sj.bjc.6603072 |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|